WilmerHale Represents Underwriters in Candel Therapeutics IPO

WilmerHale Represents Underwriters in Candel Therapeutics IPO

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the initial public offering of 9,000,000 shares of common stock of Candel Therapeutics, Inc., for aggregate gross proceeds of $72 million. The offering priced on July 26, 2021 at $8.00 per share and closed on July 29, 2021.

The team representing the underwriters consisted of Partner Lisa Firenze, Counsel Stephanie Leopold, Senior Associate Sean Linnehan and Associates Erin Bruynell and Amanda Navarro, with support from Partners Bruce Manheim and Colleen Superko and Attorney Heidi Treiber.


Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel